UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 11, 2009
OCULUS INNOVATIVE SCIENCES, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
001-33216
|
|
68-0423298 |
| |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
| 1129 N. McDowell Blvd., Petaluma, California
|
|
94954 |
| |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (707) 782-0792
Not applicable.
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 2.02 Results of Operations and Financial Condition.
On June 11, 2009, Oculus Innovative Sciences, Inc. issued a press release announcing financial
results for its fiscal year ended March 31, 2009. The full text of the press release is furnished
as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
| 99.1 |
|
Press release issued by Oculus Innovative Sciences, Inc. dated June 11, 2009. |
Except for historical information herein,
matters set forth in this report on Form 8-K are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995, including statements about the Company’s
commercial and technology progress and future financial performance. These forward-looking statements are
identified by the use of words such as “expects,” “intends,” “targeting,” “believes,” and “will be,” among
others. Forward-looking statements in this report are subject to certain risks and uncertainties inherent
in the Company’s business that could cause actual results to vary, including such risks that regulatory
clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory
standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated
in actual patient settings, protection offered by the Company’s patents and patent applications may be
challenged, invalidated or circumvented by its competitors, the available market for the Company’s products
will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted
markets, revenues will not be sufficient to fund further development and clinical studies, the Company may
not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties
relative to varying product formulations and a multitude of diverse regulatory and marketing requirements
in different countries and municipalities, and other risks detailed from time to time in the Company’s
filings with the Securities and Exchange Commission including the annual report on Form 10-K for the year
ended March 31, 2009. Oculus Innovative Sciences disclaims any obligation to update these forward-looking
statements except as required by law.